Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCNC | P24863 | 4/20 | 0.64 |
| ▸ | CDK8 | P49336 | 4/20 | 0.64 |
| ▸ | NPC1 | O15118 | 1/20 | 0.59 |
| ▸ | RAB9A | P51151 | 1/20 | 0.59 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.59 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.55 |
| ▸ | SCN10A | Q9Y5Y9 | 5/20 | 0.54 |
| ▸ | SCN2A | Q99250 | 1/20 | 0.53 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.51 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.51 |
| ▸ | SMO | Q99835 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.48 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.48 |
| ▸ | SIRT3 | Q9NTG7 | 1/20 | 0.48 |
| ▸ | ABL1 | P00519 | 2/20 | 0.48 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.48 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.48 |
| ▸ | XDH | P47989 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27828390 | 0.86 | CCNC (0.64) | CCNCCDK8NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL12190884 | 0.84 | CCNC (0.62) | CCNCCDK8NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL12191060 | 0.83 | SCN10A (0.72) | CCNCCDK8NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL27828346 | 0.82 | HTT (0.64) | CCNCCDK8NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL14640457 | 0.82 | KCNK9 (0.59) | CCNCCDK8NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL12829331 | 0.79 | NR1H4 (0.73) | NPC1RAB9ASMN1; SMN2TRPV1PTPN1 | |
| SCHEMBL10162575 | 0.79 | TRPV1 (0.71) | NPC1RAB9ASMN1; SMN2TRPV1PTPN1 | |
| SCHEMBL12191048 | 0.79 | ABL1 (0.68) | CCNCCDK8NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL28762778 | 0.79 | CCNC (1.00) | CCNCCDK8 | |
| SCHEMBL27989071 | 0.78 | KMT2A (0.62) | CCNCCDK8NPC1RAB9ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2411363-B1 | SUBSTITUTED PIPERIDINES AS PAR-1 ANTAGONISTS | BAYER IP GMBH (DE) | 2015-10-07 | — | — | EP | disclosed |
| EP-2411363-B1 | SUBSTITUTED PIPERIDINES AS PAR-1 ANTAGONISTS | BAYER IP GMBH (DE) | 2015-10-07 | — | — | EP | disclosed |
| US-20150183773-A1 | Substituted piperidines | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2015-07-02 | — | — | US | disclosed |
| US-20150183773-A1 | Substituted piperidines | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2015-07-02 | — | — | US | disclosed |
| US-20150183773-A1 | Substituted piperidines | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2015-07-02 | — | — | US | disclosed |
| US-8987248-B2 | Substituted piperidines as Par-1 antagonists | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2015-03-24 | — | — | US | disclosed |
| US-8987248-B2 | Substituted piperidines as Par-1 antagonists | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2015-03-24 | — | — | US | disclosed |
| US-8987248-B2 | Substituted piperidines as Par-1 antagonists | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2015-03-24 | — | — | US | disclosed |
| US-20120046268-A1 | Substituted piperidines as Par-1 Antagonists | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2012-02-23 | — | — | US | disclosed |
| US-20120046268-A1 | Substituted piperidines as Par-1 Antagonists | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2012-02-23 | — | — | US | disclosed |
| US-20120046268-A1 | Substituted piperidines as Par-1 Antagonists | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2012-02-23 | — | — | US | disclosed |
| EP-2411363-A1 | SUBSTITUTED PIPERIDINES AS PAR-1 ANTAGONISTS | Bayer Pharma AG (DE) | 2012-02-01 | — | — | EP | disclosed |
| WO-2010108608-A1 | SUBSTITUTED PIPERIDINES AS PAR-1 ANTAGONISTS | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2010-09-30 | — | — | WO | disclosed |
| WO-2010108608-A1 | SUBSTITUTED PIPERIDINES AS PAR-1 ANTAGONISTS | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2010-09-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150183773-A1 | Substituted piperidines | VHL, PIR, PIGO | CCNC 1101/4885CDK8 3090/4885NPC1 168/4885 |
| US-20120046268-A1 | Substituted piperidines as Par-1 Antagonists | F2R, F2RL1, F2RL3 | CCNC 2252/4885CDK8 2040/4885NPC1 871/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.